Bone age at discontinuation of medroxyprogesterone acetate therapy in girls with precocious puberty: effect on final height.
To determine the final height of patients with precocious puberty treated with medroxyprogesterone acetate (MPA; 150 mg every week) for a period > 1 year (mean +/- SD = 3.24 +/- 1.85 years), data from a group of 26 girls were analyzed. The attained final height was 155.6 +/- 8.06 cm (-1.1 SD of the normal population). In a group of 8 untreated girls with precocious puberty, adult height was 149.2 +/- 5.07 (-2.16 SD, p < 0.02). In 9 patients in whom treatment was stopped at a bone age < or = 12 years, final height was 159.2 +/- 10.05 cm, while in 16 girls who had a bone age > 12 years at the end of treatment, the final height was 153.03 +/- 6.28 cm. Our data demonstrate the effectiveness of MPA treatment on ultimate height. The better height observed in those patients who stopped treatment with a bone age < 12 years suggests the advantage of discontinuing therapy before reaching a more advanced degree of skeletal maturation.
Boulgourdjian
E
E
División de Endocrinología, CEDIE, Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina.
Escobar
M E
ME
Martinez
A
A
Heinrich
J J
JJ
Bergadá
C
C
D000365:Age Determination by Skeleton; D001827:Body Height; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D011629:Puberty, Precocious / Q000188:drug therapy*; D012189:Retrospective Studies
D017258:Medroxyprogesterone Acetate